Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
Summary
The excitement around artificial intelligence (AI) has led to most attention—and capital–being concentrated in one corne...
The excitement around artificial intelligence (AI) has led to most attention—and capital–being concentrated in one corner while forgetting others, creating a gap and massive opportunity for rotation into some of these forgotten names that still carry greatly attractive fundamental profiles.
Related Articles
Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
LLY
Positive3 Dividend Growth Stocks You Can Buy and Forget About
LLY
PositiveLilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy
LLY
Neutral